Modality
Bispecific Ab
MOA
STINGag
Target
RET
Pathway
Cell Cycle
EoEProstate Ca
Development Pipeline
Preclinical
Oct 2017
→ Oct 2028
PreclinicalCurrent
NCT06590940
409 pts·Prostate Ca
2017-10→2028-10·Not yet recruiting
409 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-202.6y awayInterim· Prostate Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2028-10-20 · 2.6y away
Prostate Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06590940 | Preclinical | Prostate Ca | Not yet recr... | 409 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |